Techne's Ella ELISA platform to run its ovarian cancer test, advancing toward FDA 510(k) filing and supply deal.

NEW YORK — Bio-Techne said on Monday that its Ella benchtop immunoassay platform has received CE-IVD marking, permitting its sale in the EU.

Bio-Techne's Ella platform achieves CE-IVD marking expanding access to rapid, cartridge-based immunoassays for European clinical labs: Minneapolis Tuesday, February 17, 2026, 14:0 ...

Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today ...

Detailed price information for Bio-Techne Corp (TECH-Q) from The Globe and Mail including charting and trades.

Dr. Matt McManus to transition from his role as President, Diagnostics and Spatial Biology Segment, effective March 1, 2026 Steve Crouse, Senior Vice President of ...

Bio-Techne Corporation (NASDAQ: TECH) today announced that Dr. Matt McManus, President of Bio-Techne's Diagnostics and ...

Bio-Techne Corporation (NASDAQ:TECH) Q2 2026 Earnings Call Transcript February 4, 2026 Bio-Techne Corporation beats earnings ...

Feb 4 (Reuters) - Biotech firm Bio-Techne (TECH.O), opens new tab beat analysts' estimates for second-quarter revenue and profit on Wednesday, helped by robust demand for its products used in drug ...

MINNEAPOLIS - Bio-Techne Corporation (NASDAQ:TECH) reported flat revenue but improved profitability in its second quarter fiscal 2026 results, with adjusted earnings per share rising to $0.46 compared ...

Life sciences company Bio-Techne (NASDAQ:TECH) reported Q4 CY2025 results , but sales were flat year on year at $295.9 million. Its non-GAAP profit of $0.46 per share was 5.8% above analysts’ ...